Skip to content
Medical Health Aged Care, Science

Mimics human tissue, fights bacteria: new biomaterial hits the sweet spot

UNSW Sydney 3 mins read

A new lab-made substance mimics human tissue and could reduce or replace the use of animal-derived materials in biomedical research.

Scientists at UNSW Sydney have created a new material that could change the way human tissue can be grown in the lab and used in medical procedures.

The new material belongs to a family of substances called hydrogels, the essence of life’s ‘squishy’ substances found in all living things, such as cartilage in animals and in plants like seaweed. The properties of hydrogels make them very useful in biomedical research because they can mimic human tissue, allowing cells to grow in a laboratory.

There are also human-made hydrogels that are used in a broad range of commodity products ranging from food and cosmetics to contact lenses and absorbent materials, and more recently in medical research to seal wounds and replace damaged tissue. While they might function adequately as space fillers that encourage tissue growth, synthetic hydrogels fall short in recreating the complex properties of real human tissue.

But in a research paper published today in Nature Communications, scientists from UNSW describe how a new lab-made hydrogel behaves like natural tissue, with a number of surprising qualities that have implications for medical, food and manufacturing technology.

Associate Professor Kris Kilian from UNSW’s School of Materials Science & Engineering and School of Chemistry says the hydrogel material is made from very simple, short peptides, which are the building blocks of proteins.

“The material is bioactive, which means that encapsulated cells behave as if they are living in natural tissue,” A/Prof. Kilian says.

“At the same time, the material is antimicrobial, meaning that it will prevent bacterial infections. This combination lands it in the sweet spot for materials that might be useful in medicine. The material is also self-healing, which means that it will reform after being squished, fractured, or after being expelled from a syringe. This makes it ideal for 3D bioprinting, or as an injectable material for medicine.”

Surprise discovery in lockdown

Ashley Nguyen, a PhD student in the UNSW School of Chemistry and first author on the paper, made this discovery during the Covid19 lockdown using computer simulations. Ms Nguyen was looking for molecules that self-assemble – where they spontaneously arrange themselves without human intervention – and stumbled upon the concept of ‘tryptophan zippers’. These are short chains of amino acids with multiple tryptophans that act as a zipper to promote self-assembly, which have been dubbed “Trpzip”.

“I was excited to identify a unique peptide sequence using computational simulations that might form a hydrogel,” says Ms Nguyen.

“After we returned to the lab, I synthesised the top candidate and was thrilled to see it actually form a gel.”

Ms Nguyen says the discovery of this hydrogel has the potential to be an ethical alternative to the widely used natural materials.

“Natural hydrogels are used all over in society—from food processing to cosmetics—but require harvest from animals which poses ethical concerns,” she says.

“Also, animal-derived materials are problematic for use in humans because of the negative immune response that occurs. With Trpzip, we have a synthetic material that not only shows potential in many areas where natural materials are currently used, but also could outperform them in others, such as clinical research.”

Real world results

To test the viability of Trpzip in biomedical research, A/Prof. Kilian’s team partnered with researcher Dr. Shafagh Waters in the School of Biomedical Sciences at UNSW Sydney, who uses Matrigel – a hydrogel harvested from mouse tumours – for the culture of patient tissue in her research.

“Matrigel has some disadvantages in research use because every batch is different. A chemically defined alternative could be cheaper and more uniform, which would prove highly beneficial to biomedical research,” says Dr Waters.   

A/Prof Kilian notes that the natural materials business is a billion-dollar industry and says the team is keen to explore pathways to commercialisation.

“We think that Trpzip hydrogels and materials like it will provide a more uniform and cost-effective alternative to animal-derived products. It would be a tremendous outcome if our material reduced the number of animals used in scientific research.”

The next phase of research will involve partnering with industry and clinical scientists to test the utility of Trpzip gels in tissue culture and explore applications that highlight the unique dynamic characteristics like 3D bioprinting and stem cell delivery.


Contact details:

Lachlan Gilbert

UNSW Media

t: +61 404 192 367

e: lachlan.gilbert@unsw.edu.au

More from this category

  • Medical Health Aged Care
  • 14/12/2024
  • 10:00
Royal Australian College of GPs

SA Premier and Health Minister join GPs in Adelaide parkrun for better health and wellbeing

South Australia’s Premier Peter Malinauskas and Minister for Health and Wellbeing Chris Picton ran alongsideRACGP President Dr Michael Wright and South Australia Chair Dr Sian Goodson in the Nantu Wama parkrun in North Adelaide this morning. The Royal Australian College of GPs partnered with non-profit parkrun Australia to support GPs across the nation in tackling rising chronic illness. RACGP President Dr Michael Wright said: “The RACGP partnered with parkrun Australia to encourage social prescribing – a powerful tool GPs can use to encourage patients to take up activities to improve their health and wellbeing. "There was great success when the…

  • Medical Health Aged Care
  • 14/12/2024
  • 09:27
Galderma

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic,…

  • Contains:
  • Medical Health Aged Care
  • 14/12/2024
  • 06:35
Monash University

Stem Cells: Hope on the Horizon for Preterm Babies

Australian researchers have discovered a potential new lifeline for the tiniest and most vulnerable newborns. Scientists at Monash Children's Hospital have successfully collected and reinfused umbilical cord blood cells in extremely premature babies, offering a glimmer of hope for preventing brain injuries. This pioneering Australian research, undertaken by a collaboration of Monash Health’s Monash Children’s Hospital, The School of Clinical Sciences at Monash University, and Hudson Institute of Medical Research, has successfully demonstrated the feasibility and safety of using a baby's own cord blood-derived cells as a potential treatment for extremely preterm infants. Published in the Lancet journal eBioMedicine, this…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.